Atopic dermatitis (AD) is a common skin disease characterized by epidermal changes with immune regulatory abnormalities. The pathogenesis of AD involves skin barrier defects, genetic factors and immune deregulation. The AD therapy includes skin hydration, anti-inflammatory agents, antibacterial medications and treatment of pruritus. Currently, topical corticosteroids (TCs) are the most frequently used drugs for the treatment of AD due to their potent immunosuppressive action. However, TCs are associated with several local and systemic side effects. The topical steroid addiction and phobia are among the major challenges with TC therapy. Over the years, efforts are being made to reduce side effects which involve adjustment of dosing, minimizing use in vulnerable areas, avoiding prolonged drug usage and application of novel drug delivery systems. The present review provides an overview of the current and upcoming delivery systems of TCs along with novel approaches being employed to improve the drug delivery in the treatment of AD.
CITATION STYLE
Sharma, K., Tharmatt, A., Salooria, S., Sharma, R., & Bedi, N. (2021). Topical Corticosteroids in Treatment of Atopic Dermatitis: An Overview of Their Current Status. Journal of Pharmaceutical Research International, 1–20. https://doi.org/10.9734/jpri/2020/v32i3831008
Mendeley helps you to discover research relevant for your work.